Breast Cancer in Women Under Age 40 Years

Vogel, Jeffery E.; Chu, Carrie K.; McCullough, Meghan; Anderson, Erica D.; Losken, Albert; Carlson, Grant W.

doi:10.1097/sap.0b013e318216b648

Cited by 11 publications

(12 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…13,40,41 Although a few studies have discussed IBR in young patients, ours is the first to stratify results according to implant placement location. 16,42 Prepectoral reconstruction has the advantage of sparing patients’ muscle-related complications, which can be especially beneficial in this younger higher risk population. 26–29 Although concerns such as rippling and capsular contracture are potential feared complications of prepectoral reconstruction, in recent practice, this has been avoided with the introduction of ADM and fat grafting.…”

Section: Discussionmentioning

confidence: 99%

“…13 Furthermore, younger patients are also more likely to choose implant-based reconstruction (IBR) than flap reconstruction due to concerns over abdominal wall morbidity, potential effect on future pregnancies, and the increased likelihood of undergoing a contralateral mastectomy. 14–16…”

Section: Introductionmentioning

confidence: 99%

“…Furthermore, comparative studies assessing outcomes of the prepectoral and subpectoral approaches are lacking. 16,37,38 The aim of this study is to compare outcomes and complications between prepectoral and subpectoral IBR in women younger than 40 years old. To our knowledge, this is the first study to address this comparison in this young age group.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Surgical Outcomes of Prepectoral Versus Subpectoral Implant-based Breast Reconstruction in Young Women

Manrique

Banuelos

Abu‐Ghname

et al. 2019

Plastic and Reconstructive Surgery - Global Open

View full text Add to dashboard Cite

Background: Two-staged implant-based reconstruction (IBR) is the most common breast reconstructive modality. Recently, technological and surgical advances have encouraged surgeons to revisit prepectoral IBR. Data comparing prepectoral against subpectoral IBR in women under the age of 40 are lacking. Methods: Retrospective chart review of patients under the age of 40 years old, who underwent immediate 2-staged IBR at our institution, was performed. Patient’s demographics, clinical characteristics, operative details, and early surgical outcomes of prepectoral and subpectoral reconstruction were compared. Data with values of P < 0.05 were considered statistically significant. Results: Between 2012 and 2016, 100 patients (187 breasts) who underwent prepectoral and 69 patients (124 breasts) who underwent subpectoral IBR were included. Median follow-up was 17.9 and 17.5 months in the prepectoral and subpectoral groups, respectively. Total number of complications including both stages of reconstruction was 20 (10.7%) and 19 (15.3%) in the prepectoral and subpectoral groups, respectively ( P = 0.227). Specific complications, including hematoma, seroma, skin flap necrosis, wound dehiscence, and breast infections, were not significantly different among groups. Ten (5.4%) devices, including implants and tissue expander, required explantation in the prepectoral group and 8 (6.5%) in the subpectoral group ( P = 0.683). Explantation was most commonly due to infection (n = 14), and all of them occurred during the first stage ( P < 0.001). Conclusions: Early complications and implant explantation rates are comparable among prepectoral and subpectoral breast reconstruction in women under 40 years old. Based on these results, we believe that prepectoral IBR is a safe, reliable, and promising reconstructive option.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Surgical Outcomes of Prepectoral Versus Subpectoral Implant-based Breast Reconstruction in Young Women

Manrique

Banuelos

Abu‐Ghname

et al. 2019

Plastic and Reconstructive Surgery - Global Open

View full text Add to dashboard Cite

show abstract

“…Breast cancer is the main cause of cancer-related deaths among females, accounting for approximately 7% of female cancer deaths due to uncontrolled metastasis ( Anders et al, 2009 ; Vogel et al, 2011 ). Lidocaine exhibited activities in suppressing breast cancer growth.…”

Section: Lidocaine In Cancer Treatmentmentioning

confidence: 99%

Repositioning Lidocaine as an Anticancer Drug: The Role Beyond Anesthesia

Zhou

Wang

Cui

et al. 2020

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

While cancer treatment has improved dramatically, it has also encountered many critical challenges, such as disease recurrence, metastasis, and drug resistance, making new drugs with novel mechanisms an urgent clinical need. The term “drug repositioning,” also known as old drugs for new uses, has emerged as one practical strategy to develop new anticancer drugs. Anesthetics have been widely used in surgical procedures to reduce the excruciating pain. Lidocaine, one of the most-used local anesthetics in clinical settings, has been found to show multi-activities, including potential in cancer treatment. Growing evidence shows that lidocaine may not only work as a chemosensitizer that sensitizes other conventional chemotherapeutics to certain resistant cancer cells, but also could suppress cancer cells growth by single use at different doses or concentrations. Lidocaine could suppress cancer cell growth in vitro and in vivo via multiple mechanisms, such as regulating epigenetic changes and promoting pro-apoptosis pathways, as well as regulating ABC transporters, metastasis, and angiogenesis, etc., providing valuable information for its further application in cancer treatment and for new drug discovery. In addition, lidocaine is now under clinical trials to treat certain types of cancer. In the current review, we summarize the research and analyze the underlying mechanisms, and address key issues in this area.

show abstract

“…Breast cancer is considered rare in young women below 40 years. About 5 to 6% of total breast cancer occurs in women younger than 40 years [ 1 ]. In the epidemiology of breast cancer, young women are said to differ according to race [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

Breast cancer in women younger than 30 years: prevalence rate and imaging findings in a symptomatic population

Makanjuola¹,

Alkushi²,

Alzaid³

et al. 2014

Pan Afr Med J

View full text Add to dashboard Cite

IntroductionTo identify the prevalence rate of primary breast cancer in women younger than 30 years of age in a symptomatic population in Riyadh, Kingdom of Saudi Arabia. To analyze the imaging pattern and possible risk factors in cases with cancer. Breast cancer in this age group is generally rare and not clearly understood.MethodsAt King Abdulaziz Medical City for National Guard, Riyadh, a retrospective 5-year (January 2006 to December 2010) data was collected from the Medical Imaging departmental records on breast imaging. Patients younger than 30 years of age were identified including those with breast cancer. The clinical presentation, risk factors, imaging findings and final outcomes were analyzed in a descriptive way. The total number of patients diagnosed with primary breast cancer was recorded.ResultsSeventeen out of a total of 4873 patients younger than 30 years examined had primary breast cancer constituting a rate of 3.5 per 1000 symptomatic patients. The age range was 17 to 29 with mean of 27. The total number of patients with primary breast cancer diagnosed during that period was 413 making a percentage of 4.1% (17 out of 413) in those younger than 30 years. First presentation with a palpable mass and imaging findings of unequivocal category 5 of Breast Imaging Reporting and Data System (BI-RADS) occurred in all. Eight patients had stage I and II while nine had stage III and IV cancers. Only 2 of the 17 had first-degree family history. The youngest was 17 years old.ConclusionA prevalence rate of 3.5 per 1000 primary cancer occurred in the symptomatic population studied and 4 in every 100 primary cancer diagnosed in the unit occurred in women younger than 30 years. First presentation, low family trait and typical imaging features of malignancy was found in all cases.

show abstract

Breast Cancer in Women Under Age 40 Years

Abstract: Breast reconstruction in women less than 40 years of age is influenced by advanced tumor stage and the necessity for adjuvant radiation therapy as well as an increased use of contralateral prophylactic mastectomy.

Cited by 11 publications

References 21 publications

Surgical Outcomes of Prepectoral Versus Subpectoral Implant-based Breast Reconstruction in Young Women

Surgical Outcomes of Prepectoral Versus Subpectoral Implant-based Breast Reconstruction in Young Women

Repositioning Lidocaine as an Anticancer Drug: The Role Beyond Anesthesia

Breast cancer in women younger than 30 years: prevalence rate and imaging findings in a symptomatic population

Contact Info

Product

Resources

About